Related references
Note: Only part of the references are listed.Single-dose safety and pharmacokinetics of ST-246, a novel Orthopoxvirus egress inhibitor
Robert Jordan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model
Scott Parker et al.
ANTIVIRAL RESEARCH (2008)
ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine
Richard N. Greenberg et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge
Kathleen A. Marriott et al.
VACCINE (2008)
Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine
Mark N. Prichard et al.
VIROLOGY JOURNAL (2008)
Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand
Wendy C. Magee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge
Sharon E. Frey et al.
VACCINE (2007)
Identification of novel antipoxviral agents: Mitoxantrone inhibits vaccinia virus replication by blocking virion assembly
Liang Deng et al.
JOURNAL OF VIROLOGY (2007)
Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus
Donald F. Smee et al.
ANTIVIRAL RESEARCH (2007)
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-Hydroxy-2-phosphonylmethoxypropyl)Adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice
Debra C. Quenelle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses
Debra C. Quenelle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model
Zhaochun Chen et al.
JOURNAL OF VIROLOGY (2007)
Selective phosphorylation of antiviral drugs by vaccinia virus thyraidine kinase
Mark N. Prichard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
IFN mimetic as a therapeutic for lethal vaccinia virus infection: Possible effects on innate and adaptive immune responses
Chulbul M. Ahmed et al.
JOURNAL OF IMMUNOLOGY (2007)
Acyclic nucleoside phosphonates: Past, present and future - Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge
E. De Clercq
BIOCHEMICAL PHARMACOLOGY (2007)
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naive and vaccinia-immune individuals
Janie Parrino et al.
VACCINE (2007)
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice
Debra C. Quenelle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Human monkeypox: an emerging zoonotic disease
Scott Parker et al.
FUTURE MICROBIOLOGY (2007)
Identification of residues in the ectromelia virus gamma interferon-binding protein involved in expanded species specificity
Anthony A. Nuara et al.
JOURNAL OF GENERAL VIROLOGY (2007)
Aurintricarboxylic acid inhibits the early stage of vaccinia virus replication by targeting both cellular and viral factors
Chad Myskiw et al.
JOURNAL OF VIROLOGY (2007)
Antiviral activity of human beta-defensin 3 against vaccinia virus
Michael D. Howell et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype
Richard S. Kornbluth et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara
Caroline Staib et al.
JOURNAL OF GENERAL VIROLOGY (2006)
Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice
Graciela Andrei et al.
JOURNAL OF VIROLOGY (2006)
Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections
MN Prichard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine
J Vollmar et al.
VACCINE (2006)
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus
ZC Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Reemergence of monkeypox: Prevalence, diagnostics, and countermeasures
A Nalca et al.
CLINICAL INFECTIOUS DISEASES (2005)
Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge
S Lustig et al.
JOURNAL OF VIROLOGY (2005)
Acyclic nucleoside phosphonates: A key class of antiviral drugs
E De Clercq et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge
G Yang et al.
JOURNAL OF VIROLOGY (2005)
A tale of two clades: monkeypox viruses
AM Likos et al.
JOURNAL OF GENERAL VIROLOGY (2005)
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin
NH Chen et al.
VIROLOGY (2005)
Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model
CA Meseda et al.
VIROLOGY (2005)
Generalized vaccinia, progressive vaccinia, and eczema vaccinatum are rare following smallpox (vaccinia) vaccination: United States surveillance, 2003
C Vellozzi et al.
CLINICAL INFECTIOUS DISEASES (2005)
Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate
WC Magee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases
PM Reeves et al.
NATURE MEDICINE (2005)
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus
KJ Stittelaar et al.
JOURNAL OF VIROLOGY (2005)
A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults
AW Artenstein et al.
VACCINE (2005)
The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program
GA Poland et al.
VACCINE (2005)
Protective effect of exogenous recombinant mouse interferon-gamma and tumour necrosis factor-alpha on ectromelia virus infection in susceptible BALB/c mice
AV Atrasheuskaya et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
Prevention of lethal respiratory vaccinia infections in mice with interferon-α and interferon-γ
G Liu et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2004)
Zoonotic poxvirus infections in humans
S Lewis-Jones
CURRENT OPINION IN INFECTIOUS DISEASES (2004)
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge
LS Wyatt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox
PL Earl et al.
NATURE (2004)
Antiviral activity of distamycin A against vaccinia virus is the result of inhibition of postreplicative mRNA synthesis
SS Broyles et al.
JOURNAL OF VIROLOGY (2004)
Smallpox, vaccination and adverse reactions to smallpox vaccine
Andreas Wollenberg et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin
E Bell et al.
VIROLOGY (2004)
Design and development of oral drugs for the prophylaxis and treatment of smallpox infection
GR Painter et al.
TRENDS IN BIOTECHNOLOGY (2004)
Bacillus anthracis incident, Kameido, Tokyo, 1993
H Takahashi et al.
EMERGING INFECTIOUS DISEASES (2004)
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox
PB Jahrling et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Clonal vaccinia virus grown in cell culture as a new smallpox vaccine
R Weltzin et al.
NATURE MEDICINE (2003)
Smallpox vaccination: A review, part II. Adverse events
VA Fulginiti et al.
CLINICAL INFECTIOUS DISEASES (2003)
Prevention of poxvirus infection by tetrapyrroles
ARM Chen-Collins et al.
BMC INFECTIOUS DISEASES (2003)
Pathogenesis and potential antiviral therapy of complications of smallpox vaccination
M Bray
ANTIVIRAL RESEARCH (2003)
An epidemiological analysis of the 1971 smallpox outbreak in Aralsk, Kazakhstan
AP Zelicoff
CRITICAL REVIEWS IN MICROBIOLOGY (2003)
Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections
R Baker et al.
ANTIVIRAL RESEARCH (2003)
Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001
H Meyer et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2002)
Current concepts - Diagnosis and management of smallpox
JG Breman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis)
GM Zaucha et al.
LABORATORY INVESTIGATION (2001)
Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro
DF Smee et al.
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY (2001)
Developing new smallpox vaccines
SR Rosenthal et al.
EMERGING INFECTIOUS DISEASES (2001)
Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox
RJ Jackson et al.
JOURNAL OF VIROLOGY (2001)
Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir
DF Smee et al.
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY (2000)
Share Paper
